IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4636
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$26M
Matthias G. Schroff
Exicure, Inc. develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$XCUR EXICURE, INC. | 28 | 17 | 22 | 17 | - | - | -45.3% | -20.6% | - | - | - | - | 0.0% | 120.0x | $26M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
EXICURE, INC. (XCUR) receives a "Avoid" rating with a composite score of 28.2/100. It ranks #4636 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for XCUR.
View All RatingsROE proxy -45.3% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate EXICURE, INC. (XCUR) as Avoid with a composite score of 28.2/100 at a current price of $3.59. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
EXICURE, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 28.2/100 places it at rank #4636 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Leverage of 120% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
EXICURE, INC. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags EXICURE, INC. with an Avoid rating, assigning a composite score of 28.2/100 and 1 out of 5 stars. Ranked #4636 of 7,333 stocks, XCUR falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
EXICURE, INC. registers a weak quality score of just 17/100, indicating significant profitability challenges. The company reports a return on equity of -45.3% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
XCUR registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.29x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
EXICURE, INC.'s investment score of 37/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -20.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
EXICURE, INC. is experiencing notably weak momentum with a score of just 17/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of -0.28 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
XCUR's stability score of 37/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -0.28 and a debt-to-equity ratio of 120.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
XCUR carries a short interest score of 65/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 120.00x), micro-cap liquidity risk. At $26M market cap (micro-cap), EXICURE, INC. offers reasonable institutional liquidity.
EXICURE, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4636 of 7,333 overall (37th percentile). Key comparisons include ROE of -45.3% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While XCUR currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (17) would have the largest impact on the composite score.
ROE 2285% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 57043% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. FMC posted adjusted earnings of $1.07 per share, missing market estimates of $1.08 per share. The company’s quarterly sales came in at $1.15 billion versus expectations of $1.25 billion. FMC shares dipped 9.8% to $54.51 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) jumped 144.4% to $0.5427 after dipping around 26% on Monday. Tenax Therapeutics, Inc. (NASDAQ: TENX) jumped 96% to $17.13 after the company announced the USPTO granted notice of allowance for the U.S. patent application "Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction." Agrify Corporation (NASDAQ: AGFY) shares climbed 70.1% to $1.0889. Agrify achieved milestone with PX-30 hydrocarbon extraction system installation in Michigan Facility. ADDvantage Technologies Group, Inc. (NASDAQ: AEY) gained 36% to $0.4769. Palantir Technologies Inc. (NYSE: PLTR) shares surged 27% to $21.23 after the company reported better-than-expected fourth-quarter sales results and issued guidance. Zenvia Inc. (NASDAQ: ZENV) rose 25% to $1.4621. Zenvia announced agreements to address funding gap and introduced EBITDA guidance for 2024, with a range between BRL 120 million and BRL140 million. Helius Medical Technologies, Inc. (NASDAQ: HSDT) climbed 24% to $8.80. Helius Medical Technologies announced alignment with the FDA on registrational program for treatment of stroke patients. Exicure, Inc. (NASDAQ: XCUR) gained 21.7% to $0.67 after the company announced it entered ...
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance. Palantir said fourth-quarter revenue increased 20% year-over-year to $608 million, which beat the consensus estimate of $602.41 million, according to Benzinga Pro. Palantir reported quarterly adjusted earnings of 8 cents per share, which was in line with analyst estimates. Palantir expects first-quarter revenue to be between $612 million and $616 million versus estimates of $617.21 million. First-quarter adjusted income from operations is expected to be between $196 million and $200 million. Palantir Technologies shares jumped 18.2% to $19.77 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) gained 54.2% to $0.3424 in pre-market trading after dipping around 26% on Monday. Chenghe Acquisition Co. (NASDAQ: CHEA) shares jumped 43.2% to $10.08 in pre-market trading. Chenghe Acquisition shares jumped 28% on Monday after shareholders on Friday voted to approve the merger agreement with Taiwan Color Optics, Inc. Exicure, Inc. (NASDAQ: XCUR) gained 36.2% to $0.75 ...
Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted weaker-than-expected results for its second quarter. Richardson Electronics posted a quarterly loss of 13 cents per share, compared to market estimates for earnings of 1 cent per share. The company’s quarterly sales came in at $44.13 million versus estimates of $52.00 million, according to data from Benzinga Pro. Richardson Electronics shares dipped 13.2% to $10.85 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Atreca, Inc. (NASDAQ: BCEL) shares rose 53.2% to $0.1641 in pre-market trading after falling around 7% on Wednesday. Atreca, last month, announced the sale of a collection of antibody-related assets and materials to Immunome consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. Bitcoin Depot Inc. (NASDAQ: BTM) shares jumped 31.8% to $3.48 in pre-market trading amid strength in the price of Bitcoin. U.S. regulators gave the green light to Bitcoin ETFs. Transphorm, Inc. (NASDAQ: TGAN) surged 30.6% to $4.95 in pre-market trading. after ...
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. WD-40 reported quarterly earnings of $1.28 per share which exceeded the analyst consensus estimate of $1.05 per share. The company reported quarterly sales of $140.42 million, clocking in above the Street's estimate of $134.37 million. WD-40 shares jumped 17.3% to $277.56 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Nauticus Robotics, Inc. (NASDAQ: KITT) climbed 87.8% to $0.5501. Nauticus Robotics secured additional funding and appointed John W. Gibson, Jr as interim CEO. Clearmind Medicine Inc. (NASDAQ: CMND) shares jumped 47.7% to $3.0570. Clearmind Medicine completed a Type A Meeting with the FDA for clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of alcohol use disorder. Sana Biotechnology, Inc. (NASDAQ: SANA) gained 46.8% to $7.57. Sana Biotechnology recently announced FDA clearance of investigational new drug application for SC262. Ucommune International Ltd (NASDAQ: UK) jumped 37.8% to $4.98. Vicarious Surgical Inc. (NASDAQ: RBOT) rose 37% to $0.6851. Nvni Group Limited (NASDAQ: NVNI) climbed 35.2% to $2.6091. EchoStar Corporation (NASDAQ: SATS) gained 31% to $16.50. EchoStar completed merger with DISH Network Corporation. Amarin Corporation plc (NASDAQ: AMRN) climbed 28.8% to $1.25 after the company reported strong preliminary FY23 total revenues. Exicure, Inc. (NASDAQ: XCUR) shares rose 17% to $0.5501. Exicure was granted broad U.S. patent #11866700 for "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin ...
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. Icosavax shares gained 44.8% to $15.19 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares rose 76.8% to $0.2882 in pre-market trading after gaining over 5% on Monday. Connect Biopharma Holdings Limited (NASDAQ: CNTB) rose 32.2% to $1.19 in pre-market trading. Connect Biopharma will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Dec. 12, 2023. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 28% to $0.3159 in pre-market trading. Kaival Brands recently appointed James W. Dobbins as General Counsel. IN8bio, Inc.(NASDAQ: INAB) gained ...
Above 50MA
37.18%
Net New Highs
+51081